EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 October 2016
EMA/CHMP/179671/2016
Committee for Medicinal Products for Human Use (CHMP)

Concept paper on the need for revision of the guideline on clinical investigation of medicinal product for the treatment of migraine

Agreed by CNS Working Party	June 2016
Adopted by CHMP for release for consultation	13 October 2016
Start of public consultation	21 October 2016
End of consultation (deadline for comments)	31 January 2017

The proposed guideline will replace the Guideline on clinical investigation of medicinal products in the treatment of migraine (CPMP/EWP/788/01 Rev.1, 24 January 2007).

Comments should be provided using this template. The completed comments form should be sent to cnswpsecretariat@ema.europa.eu.

Keywords	Migraine, acute migraine, chronic migraine, migraine prophylaxis.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

1. Introduction

Migraine is characterised recurrent severe headache attacks usually accompanied by nausea, vomiting, photo- and/or phonophobia. Attacks may last for 4-72 hours in adults. The one-year prevalence in adults is estimated to be 15%. In children and adolescents the prevalence is approximately 5 %. Three times as many women are affected as men and most sufferers are aged between 20 and 50 years; prevalence declines after 50 years. Lost workdays per year due to migraine in the general employed population have been estimated at almost 6 days per 1000 working persons.

The current guideline (CHMP/EWP/788/01 Rev.1) came into effect in July 2007. The document focusses on the evidence needed in support of a claim of treatment of acute migraine attacks and the evidence needed in support of migraine prophylaxis.

2. Problem statement

The current guideline does not address the evidence needed to support a claim of treatment of chronic migraine, which is a relatively new concept. Chronic migraine has been accepted in the International Classification of Headache Disorders (3rd edition) and has been accepted as a restricted indication for Botox®. Recently a number of scientific advice procedures have been considered for development programs of medicinal products for the treatment of chronic migraine. The other parts of the guideline still apply and are up to date although a slight adaptation may be discussed.

3. Discussion (on the problem statement)

The following critical aspects should be discussed in the update of the guidance document:

Design of the studies in chronic migraine with respect to:

- Determination of the study population (separation from medication overuse headache vs chronic headache vs chronic migraine)
- Design of the studies: Randomised placebo-controlled and active controlled parallel group studies with justification of control used
- Duration of the studies in chronic migraine , need for showing maintenance of effect
- Primary and secondary endpoints (migraine days vs headache days vs number of attacks, symptom severity)
- Methods to deal with concomitant medication for headache.

4. Recommendation

The Central Nervous System Working Party (CNSWP) recommends drafting a revision of the Migraine guideline including chronic migraine.

5. Proposed timetable

It is planned to release for consultation a draft CHMP guidance document not later than Q4 2017.

6. Resource requirements for preparation

The preparation of this guideline will involve the CNSWP. Drafts of the document will be discussed with the SAWP and other relevant WPs and committees.

7. Impact assessment (anticipated)

It is aimed that this guideline will be helpful to achieve consensus in the evaluation and standardisation of the clinical development plan for agents evaluated for migraine including chronic migraine.

8. Interested parties

The interested parties in the guidance document include learned societies and academia (International Headache Society (HIS), European Neurological Society (ENS), pharmaceutical industry (e.g. EFPIA and others) and other regulatory agencies.

9. References to literature, guidelines, etc.

Note for guidance on clinical investigation of medicinal products in treatment of Migraine

http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003481

Procedure for European Union guidelines and related documents within the pharmaceutical legislative framework (EMEA/P/24143/2004): http://www.emea.europa.eu/pdfs/human/regaffair/2414304en.pdf